AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said AbbVie Inc. ABBV is a very solid pharmaceutical company. The company has good dividend yield and attractive valuations, he added.

On Thursday, AbbVie released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansine (Elahere) monotherapy in heavily pre-treated patients with folate receptor-alpha (FRα) positive, platinum-sensitive ovarian cancer (PSOC).

Bill Baruch of Blue Line Capital said IQVIA Holdings Inc. IQV has been kind of punished in the recent weeks, but analysts at Goldman Sachs initiated coverage on the stock with a price target of $270.

On Thursday, Goldman Sachs analyst Matthew Sykes initiated coverage on IQVIA with a Buy rating and announced a price target of $270.

Don't forget to check out our premarket coverage here

Kevin Simpson of Capital Wealth Planning said The Goldman Sachs Group, Inc. GS has great dividend and low multiple.

On May 7, Wells Fargo analyst Mike Mayo maintained Goldman Sachs with an Overweight rating and raised the price target from $450 to $504.

Karen Firestone of Aureus Asset Management named Amazon.com, Inc. AMZN as her final trade.

Amazon.com has reportedly agreed to purchase certain assets of Indian video streaming service MX Player from local media giant Times Internet in an attempt to enhance its presence in smaller cities and towns in India.

Price Action:

• AbbVie shares rose 1.9% to close at $168.57 on Thursday.
• IQVIA Holdings shares rose 0.7% to close at $220.49 during Thursday's session.
• Goldman Sachs fell 0.8% to settle at $458.10 during Thursday's session.
• Amazon.com shares rose 2.1% to close at $185.00 on Thursday.

Check This Out: Over $12M Bet On PBF Energy? Check Out These 3 Stocks Insiders Are Buying